The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Phase 2

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Phase 2 · 33 people · 1 site in United States · Recruiting now

August 8, 2026
A Study of JMT203 in Patients With Cancer Cachexia

Phase 2 · randomised · 307 people · 1 site in China · Recruiting now

August 8, 2026
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Phase 2 · 90 people · 1 site in United States · Recruiting now

August 8, 2026
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer

Phase 2 · 60 people · 1 site in China · Recruiting now

August 8, 2026
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 2 · 1,130 people · 32 sites in United States · Recruiting now

August 8, 2026
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Phase 2 · 180 people · 41 sites in 8 countries · Recruiting now

August 8, 2026
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Phase 2 · 40 people · 7 sites in United States · Recruiting now

August 8, 2026
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 2 · 336 people · 15 sites in 3 countries · Recruiting now

August 8, 2026
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 2 · 252 people · 8 sites in 3 countries · Recruiting now

August 8, 2026
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 · 37 people · 7 sites in United States · Recruiting now

August 8, 2026